Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment.
Xia B, Lin K, Wang X, Chen F, Zhou M, Li Y, Lin Y, Qiao Y, Li R, Zhang W, He X, Zou F, Li L, Lu L, Chen C, Li W, Zhang H, Liu B.
Xia B, et al. Among authors: lin y, lin k.
Mol Ther Oncolytics. 2023 Jul 28;30:86-102. doi: 10.1016/j.omto.2023.07.007. eCollection 2023 Sep 21.
Mol Ther Oncolytics. 2023.
PMID: 37593111
Free PMC article.